
WHAT IS CLAIMED IS:

1. A compound, or a pharmaceutically acceptable salt thereof, having a structure of Formula (K):



(K)

wherein:

each R^{1a}, R^{1b}, R^{1c}, and R^{1d} is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-NO_2$, or -CN;

alternatively, two R^{1a} groups on adjacent ring atoms are combined to form a C_{4-8} cycloalkyl or 4 to 8 membered heterocycloalkyl having 1 to 2 heteroatoms, each independently N, O, or S;

R^{2a} and R^{2b} are each independently H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy;

alternatively, R^{2a} and R^{2b} are combined to form a 4 to 8 membered heterocycloalkyl having 1 to 2 heteroatoms, each independently N, O, or S;

R^3 is H, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy;


R^{3a} is absent or C_{1-6} alkyl;

alternatively, R^3 and R^{3a} are combined to form a 3 to 8 membered heterocycloalkyl having 1 to 2 heteroatoms, each independently N, O, or S;


subscripts m and p are each independently 0 to 2; and

subscripts n and r are each independently 0 to 3.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having a structure of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id):




(Ia)



(Ib)



(Ic)



(Id).


3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R^{1a} is H.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are each independently ethyl.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^3 is H or $C_{1\text{-}6}$ alkyl.


6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^3 is methyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, having the following structure:




.

8. The compound of any one of claims 1 to 7, having the following structure:




.


9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the following structure:




,



,




, or




.

10. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the following structure:




.


11. The compound of any one of claims 1 to 7, having the following structure:




12. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the following structure:




13. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the following structure:




14. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the following structure:



15. The compound of claim 1, having the following structure:



16. A crystalline compound of (7a*S*,10*R*)-10-(diethylcarbamoyl)-8,8-dimethyl-7a,8,9,10-tetrahydro-7*H*-indolo[7,1-*fg*][1,7]naphthyridin-8-ium iodide having the following structure:



characterized by unit cell dimensions of a = 7.0716(6) Å, α = 90°, b = 14.4326(12) Å, β = 90°, c = 23.0876(19) Å, and γ = 90°.

17. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof.

18. A use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease, wherein the medicament comprises a therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof.

19. A use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for increasing neural plasticity, wherein the compound, or the pharmaceutically acceptable salt thereof, contacts a neuronal cell in an amount sufficient to increase neural plasticity of the neuronal cell, wherein the compound produces a maximum number of dendritic crossings with an increase of greater than 1.0 fold by a Sholl Analysis.

20. A use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for increasing neural plasticity and increasing dendritic spine density, wherein the compound, or the pharmaceutically acceptable salt thereof, contacts a neuronal cell in an amount sufficient to increase neural plasticity and increase dendritic spine density of the neuronal cell.